NASDAQ:KZR Kezar Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.04 +0.12 (+2.03%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$5.76▼$6.1550-Day Range$4.58▼$14.9152-Week Range$4.30▼$18.55Volume2.68 million shsAverage Volume942,574 shsMarket Capitalization$364.94 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KZR Stock Forecast (MarketRank)Overall MarketRank™1.93 out of 5 starsMedical Sector661st out of 1,418 stocksPharmaceutical Preparations Industry315th out of 679 stocksAnalyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.67, Kezar Life Sciences has a forecasted upside of 175.9% from its current price of $6.04.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesKezar Life Sciences has received 124 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKezar Life Sciences has received 89 “underperform” votes. (Add your “underperform” vote.)Community SentimentKezar Life Sciences has received 58.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote “Outperform” if you believe KZR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions71.03% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to grow in the coming year, from ($1.19) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kezar Life Sciences (NASDAQ:KZR)Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.Read More KZR Stock News HeadlinesJune 10, 2022 | finance.yahoo.comDown 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a TurnaroundJune 6, 2022 | morningstar.comKezar Life Sciences Inc - Stock NewsMay 23, 2022 | finance.yahoo.comAfter Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)May 23, 2022 | finance.yahoo.comKezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowMay 13, 2022 | finance.yahoo.comKezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 11, 2022 | finance.yahoo.comHealth Check: How Prudently Does Kezar Life Sciences (NASDAQ:KZR) Use Debt?May 5, 2022 | finance.yahoo.comKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 4, 2022 | finance.yahoo.comWells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock PlungesMay 4, 2022 | marketwatch.comKezar Life Sciences Shares Slide Premarket on Zetomipzomib Study >KZRMay 4, 2022 | markets.businessinsider.comWhy Kezar Life Sciences Shares Are Getting HammeredMay 4, 2022 | finance.yahoo.comKezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation DiseaseMay 3, 2022 | seekingalpha.comKezar Life Sciences crashes after setback to lead asset in mid-stage trialMay 3, 2022 | finance.yahoo.comKezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and PolymyositisSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees56Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/25/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$16.67 High Stock Price Forecast$22.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+175.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-33.99% Return on Assets-31.15% Debt Debt-to-Equity Ratio0.04 Current Ratio35.25 Quick Ratio35.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.01 per share Price / Book1.51Miscellaneous Outstanding Shares60,420,000Free Float55,764,000Market Cap$364.94 million OptionableNot Optionable Beta0.54 Kezar Life Sciences Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kezar Life Sciences stock. View analyst ratings for Kezar Life Sciences or view top-rated stocks. What is Kezar Life Sciences' stock price forecast for 2022? 3 Wall Street analysts have issued twelve-month price targets for Kezar Life Sciences' stock. Their KZR stock forecasts range from $14.00 to $22.00. On average, they expect Kezar Life Sciences' share price to reach $16.67 in the next twelve months. This suggests a possible upside of 175.9% from the stock's current price. View analysts' price targets for Kezar Life Sciences or view top-rated stocks among Wall Street analysts. How has Kezar Life Sciences' stock price performed in 2022? Kezar Life Sciences' stock was trading at $16.72 at the beginning of the year. Since then, KZR shares have decreased by 63.9% and is now trading at $6.04. View the best growth stocks for 2022 here. When is Kezar Life Sciences' next earnings date? Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Kezar Life Sciences. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. View Kezar Life Sciences' earnings history. Who are Kezar Life Sciences' key executives? Kezar Life Sciences' management team includes the following people: Mr. John Franklin Fowler, Co-Founder, CEO & Director (Age 49, Pay $905.06k)Dr. Christopher J. Kirk Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 49, Pay $658.81k)Dr. Noreen Roth Henig M.D., Chief Medical Officer (Age 57, Pay $705.53k)Dr. Jack Taunton Ph.D., Co-FounderMr. Marc L. Belsky, CFO & Sec. (Age 67)Mr. Michael Wolfe, VP of Fin. & Bus. OperationsMs. Gitanjali Jain, VP of Investor Relations & External AffairsMr. Mark Schiller, Sr. VP of Legal AffairsDr. Neel K. Anand Ph.D., VP of Medicinal Chemistry & Head of Drug DiscoveryMs. Pattie Chiang, VP & Corp. Controller Who are some of Kezar Life Sciences' key competitors? Some companies that are related to Kezar Life Sciences include Madrigal Pharmaceuticals (MDGL), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Sierra Oncology (SRRA), BELLUS Health (BLUSF), Zentalis Pharmaceuticals (ZNTL), Myovant Sciences (MYOV), Day One Biopharmaceuticals (DAWN), Prothena (PRTA), Agios Pharmaceuticals (AGIO), Cassava Sciences (SAVA), 23andMe (ME), Kura Oncology (KURA), NGM Biopharmaceuticals (NGM) and IVERIC bio (ISEE). View all of KZR's competitors. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO. What is Kezar Life Sciences' stock symbol? Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR." Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bellevue Group AG (8.23%), BlackRock Inc. (5.11%), State Street Corp (3.95%), Vanguard Group Inc. (3.93%), Victory Capital Management Inc. (3.09%) and Northern Trust Corp (0.77%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Michael Kauffman, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View institutional ownership trends for Kezar Life Sciences. Which major investors are selling Kezar Life Sciences stock? KZR stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Bellevue Group AG, Invesco Ltd., Prosight Management LP, Renaissance Technologies LLC, EAM Investors LLC, Citigroup Inc., and Bank of America Corp DE. View insider buying and selling activity for Kezar Life Sciences or view top insider-selling stocks. Which major investors are buying Kezar Life Sciences stock? KZR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State Street Corp, Vanguard Group Inc., BlackRock Inc., Goldman Sachs Group Inc., Slow Capital Inc., Ghost Tree Capital LLC, and Simplex Trading LLC. View insider buying and selling activity for Kezar Life Sciences or or view top insider-buying stocks. How do I buy shares of Kezar Life Sciences? Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kezar Life Sciences' stock price today? One share of KZR stock can currently be purchased for approximately $6.04. How much money does Kezar Life Sciences make? Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $364.94 million. The company earns $-54.63 million in net income (profit) each year or ($1.04) on an earnings per share basis. How many employees does Kezar Life Sciences have? Kezar Life Sciences employs 56 workers across the globe. How can I contact Kezar Life Sciences? Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Kezar Life Sciences is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at [email protected]. This page (NASDAQ:KZR) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
